---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-21-003055"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2021-11-04T23:59:59+00:00"
generated_at: "2026-06-28T12:49:15.613194+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics Q3 cash $803.6M; FT596/FT516 show 71% and 73% ORR in lymphoma Ph1

## Summary
- Cash, equivalents and investments $803.6M at Sept 30, 2021; revenue $14.2M from collaborations.
- FT596 in r/r BCL: 71% ORR, 50% CR in single-dose cohorts; no ICANS or GVHD, two low-grade CRS events.
- FT516 in r/r BCL: 73% ORR, 55% CR in multi-dose cohorts; 63% responders ongoing at median 5.2 months.
- FT819 (iPSC-derived CAR T) first patients dosed; FT576 Ph1 enrollment initiated for multiple myeloma.
- R&D expenses $53.1M, G&A $15.7M; shares outstanding 95.4M common, 2.8M preferred (convertible 5:1).

## SEC filing metadata
- accession: 0000950170-21-003055
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2021-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000095017021003055/0000950170-21-003055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000095017021003055/fate-20211104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-21-003055
- JSON: https://secwatch.observer/filing/0000950170-21-003055.json
- Plain text: https://secwatch.observer/filing/0000950170-21-003055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.